Caxton Associates LP Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Caxton Associates LP acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 300,000 shares of the medical device company's stock, valued at approximately $23,331,000. DexCom comprises 0.7% of Caxton Associates LP's portfolio, making the stock its 22nd biggest position. Caxton Associates LP owned about 0.08% of DexCom at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom in the 4th quarter worth $25,000. Private Trust Co. NA lifted its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new position in DexCom in the 4th quarter valued at about $33,000. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 over the last three months. 0.32% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research analyst reports. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Canaccord Genuity Group raised their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Barclays lifted their price objective on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $98.11.

DexCom Trading Up 2.2 %

DexCom stock traded up $1.82 during midday trading on Wednesday, reaching $83.35. The stock had a trading volume of 3,944,543 shares, compared to its average volume of 4,294,290. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $32.68 billion, a price-to-earnings ratio of 58.29, a PEG ratio of 2.30 and a beta of 1.43. The firm's fifty day simple moving average is $71.05 and its two-hundred day simple moving average is $77.00.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.